



Minivelle® (estradiol) – First-time generic

- On November 2, 2018, [Noven's Grove Pharmaceuticals launched](#) an authorized generic version of Noven's [Minivelle \(estradiol\)](#) transdermal patches.
 - Mylan received [FDA approval](#) of [AB-rated](#) generic versions of Minivelle on August 15, 2018. Launch plans for this product are pending.
- Minivelle is approved for the treatment of moderate to severe vasomotor symptoms due to menopause and for the prevention of postmenopausal osteoporosis.
- Minivelle carries a boxed warning for endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.